Qyuns Therapeutics Partners with Windward Bio Affiliate for Global Development of QX027N

Reuters2025-12-22

Qyuns <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Partners with Windward Bio Affiliate for Global Development of QX027N

Qyuns Therapeutics Co. Ltd. has announced that it has entered into a license and collaboration agreement with LE2025 Therapeutics AG, an affiliate of Windward Bio Group AG. Under the agreement, LE2025 will receive exclusive rights to develop and commercialize QX027N, a long-acting anti-TSLPxIL-13 bispecific antibody, outside of mainland China, Taiwan, Hong Kong, and Macau. Qyuns Therapeutics will be eligible to receive payments totaling up to USD $700 million, including an upfront payment, equity interest in Windward Bio, development and commercial milestone payments, and tiered royalties on net sales of QX027N in the licensed territories. QX027N is being developed for the treatment of asthma and atopic dermatitis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qyuns Therapeutics Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251222-11962841), on December 22, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2593127179?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-22 08:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593127179","market":"nz","top_or_hot":-1,"title":"Qyuns Therapeutics Partners with Windward Bio Affiliate for Global Development of QX027N","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Qyuns <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Partners with Windward Bio Affiliate for Global Development of QX027N\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Qyuns Therapeutics Co. Ltd. has announced that it has entered into a license and collaboration agreement with LE2025 Therapeutics AG, an affiliate of Windward Bio Group AG. Under the agreement, LE2025 will receive exclusive rights to develop and commercialize QX027N, a long-acting anti-TSLPxIL-13 bispecific antibody, outside of mainland China, Taiwan, Hong Kong, and Macau. Qyuns Therapeutics will be eligible to receive payments totaling up to USD $700 million, including an upfront payment, equity interest in Windward Bio, development and commercial milestone payments, and tiered royalties on net sales of QX027N in the licensed territories. QX027N is being developed for the treatment of asthma and atopic dermatitis.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qyuns Therapeutics Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251222-11962841), on December 22, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Qyuns Therapeutics Partners with Windward Bio Affiliate for Global Development of QX027N</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQyuns Therapeutics Partners with Windward Bio Affiliate for Global Development of QX027N\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-22 08:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Qyuns <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Partners with Windward Bio Affiliate for Global Development of QX027N\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Qyuns Therapeutics Co. Ltd. has announced that it has entered into a license and collaboration agreement with LE2025 Therapeutics AG, an affiliate of Windward Bio Group AG. Under the agreement, LE2025 will receive exclusive rights to develop and commercialize QX027N, a long-acting anti-TSLPxIL-13 bispecific antibody, outside of mainland China, Taiwan, Hong Kong, and Macau. Qyuns Therapeutics will be eligible to receive payments totaling up to USD $700 million, including an upfront payment, equity interest in Windward Bio, development and commercial milestone payments, and tiered royalties on net sales of QX027N in the licensed territories. QX027N is being developed for the treatment of asthma and atopic dermatitis.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qyuns Therapeutics Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251222-11962841), on December 22, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02509","symbol_name":"荃信生物-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL5d8lLb:1","article_id":"2593127179","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593127179","pubTimestamp":1766362076,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Qyuns Therapeutics Co. Ltd. has announced that it has entered into a license and collaboration agreement with LE2025 Therapeutics AG, an affiliate of Windward Bio Group AG. Under the agreement, LE2025 will receive exclusive rights to develop and commercialize QX027N, a long-acting anti-TSLPxIL-13 bispecific antibody, outside of mainland China, Taiwan, Hong Kong, and Macau. Qyuns Therapeutics will be eligible to receive payments totaling up to USD $700 million, including an upfront payment, equity interest in Windward Bio, development and commercial milestone payments, and tiered royalties on net sales of QX027N in the licensed territories. QX027N is being developed for the treatment of asthma and atopic dermatitis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02509":"荃信生物-B","BK1161":"生物科技"},"translate_title":"Qyuns Therapeutics与Windward Bio附属公司合作进行QX027N的全球开发","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02509":0.9},"content_text":"Qyuns Therapeutics Partners with Windward Bio Affiliate for Global Development of QX027N\n    \n\n        Qyuns Therapeutics Co. Ltd. has announced that it has entered into a license and collaboration agreement with LE2025 Therapeutics AG, an affiliate of Windward Bio Group AG. Under the agreement, LE2025 will receive exclusive rights to develop and commercialize QX027N, a long-acting anti-TSLPxIL-13 bispecific antibody, outside of mainland China, Taiwan, Hong Kong, and Macau. Qyuns Therapeutics will be eligible to receive payments totaling up to USD $700 million, including an upfront payment, equity interest in Windward Bio, development and commercial milestone payments, and tiered royalties on net sales of QX027N in the licensed territories. QX027N is being developed for the treatment of asthma and atopic dermatitis.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qyuns Therapeutics Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251222-11962841), on December 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593127179","isCrawlerRequest":true}